Omeros Other Long-Term Assets 2010-2024 | OMER

Omeros other long-term assets from 2010 to 2024. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Omeros Annual Other Long-Term Assets
(Millions of US $)
2023 $140
2022 $124
2021 $141
2020 $1
2019 $1
2018 $1
2017 $6
2016 $6
2015 $11
2014 $1
2013 $1
2012 $1
2011 $0
2010 $0
2009 $0
Omeros Quarterly Other Long-Term Assets
(Millions of US $)
2024-09-30 $131
2024-06-30 $134
2024-03-31 $137
2023-12-31 $140
2023-09-30 $121
2023-06-30 $117
2023-03-31 $121
2022-12-31 $124
2022-09-30 $145
2022-06-30 $128
2022-03-31 $135
2021-12-31 $141
2021-09-30 $1
2021-06-30 $1
2021-03-31 $1
2020-12-31 $1
2020-09-30 $1
2020-06-30 $1
2020-03-31 $1
2019-12-31 $1
2019-09-30 $1
2019-06-30 $1
2019-03-31 $1
2018-12-31 $1
2018-09-30 $6
2018-06-30 $6
2018-03-31 $6
2017-12-31 $6
2017-09-30 $6
2017-06-30 $6
2017-03-31 $6
2016-12-31 $6
2016-09-30 $11
2016-06-30 $11
2016-03-31 $11
2015-12-31 $11
2015-09-30 $1
2015-06-30 $1
2015-03-31 $1
2014-12-31 $1
2014-09-30 $1
2014-06-30 $1
2014-03-31 $1
2013-12-31 $1
2013-09-30 $1
2013-06-30 $1
2013-03-31 $1
2012-12-31 $1
2012-09-30 $1
2012-06-30 $1
2012-03-31 $1
2011-12-31 $0
2011-09-30 $0
2011-06-30 $0
2011-03-31 $0
2010-12-31 $0
2010-09-30 $0
2010-06-30 $0
2010-03-31 $0
2009-12-31 $0
2009-09-30 $0
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.448B $0.000B
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $203.382B 25.94
Stryker (SYK) United States $148.728B 33.52
Boston Scientific (BSX) United States $134.855B 38.77
EssilorLuxottica (ESLOY) France $111.549B 0.00
Medtronic (MDT) Ireland $108.676B 16.14
Haleon (HLN) United Kingdom $43.230B 28.09
Lonza Group Ag (LZAGY) Switzerland $42.368B 0.00
GE HealthCare Technologies (GEHC) United States $37.464B 19.43
ResMed (RMD) United States $35.759B 29.39
Terumo (TRUMY) Japan $29.367B 41.47
Koninklijke Philips (PHG) Netherlands $24.796B 18.98
Zimmer Biomet Holdings (ZBH) United States $21.580B 13.74
Insulet (PODD) United States $18.378B 73.18
Baxter (BAX) United States $16.844B 10.96
Smith & Nephew SNATS (SNN) United Kingdom $10.947B 0.00
BellRing Brands (BRBR) United States $9.886B 39.63
Bio-Rad Laboratories (BIO) United States $9.115B 30.98
Demant (WILYY) Denmark $8.342B 0.00
Lantheus Holdings (LNTH) United States $6.071B 14.11
TG Therapeutics (TGTX) United States $5.378B 0.00
Haemonetics (HAE) United States $4.291B 20.94
Prestige Consumer Healthcare (PBH) United States $4.157B 20.67
ICU Medical (ICUI) United States $4.134B 39.36
Perrigo (PRGO) Ireland $3.694B 10.88
Envista Holdings (NVST) United States $3.681B 27.42
Agios Pharmaceuticals (AGIO) United States $3.167B 0.00
Neogen (NEOG) United States $3.159B 36.45
Shandong Weigao Medical Polymer (SHWGF) China $3.010B 0.00
GN Store Nord (GNNDY) Denmark $2.782B 17.84
QuidelOrtho (QDEL) United States $2.548B 16.40
LeMaitre Vascular (LMAT) United States $2.380B 57.85
Warby Parker (WRBY) United States $2.366B 0.00
Green Thumb Industries (GTBIF) United States $1.977B 34.59
AtriCure (ATRC) United States $1.740B 0.00
InMode (INMD) Israel $1.552B 9.34
AdaptHealth (AHCO) United States $1.331B 9.51
Curaleaf Holdings (CURLF) Canada $1.293B 0.00
Maravai LifeSciences Holdings (MRVI) United States $1.253B 0.00
BioLife Solutions (BLFS) United States $1.178B 0.00
Phibro Animal Health (PAHC) United States $0.962B 16.97
Owens & Minor (OMI) United States $0.943B 7.37
National Vision Holdings (EYE) United States $0.910B 30.40
CeriBell (CBLL) United States $0.904B 0.00
Evolus (EOLS) United States $0.826B 0.00
Capricor Therapeutics (CAPR) United States $0.809B 0.00
VAREX IMAGING (VREX) United States $0.679B 30.02
Surmodics (SRDX) United States $0.561B 0.00
Cresco Labs (CRLBF) United States $0.561B 0.00
Verano Holdings (VRNOF) United States $0.554B 0.00
Quanterix (QTRX) United States $0.450B 0.00
Canopy Growth (CGC) Canada $0.407B 0.00
ZimVie (ZIMV) United States $0.379B 31.95
Valneva SE (VALN) France $0.359B 0.00
Viemed Healthcare (VMD) United States $0.339B 32.26
Biote (BTMD) United States $0.334B 7.31
Sanara MedTech (SMTI) United States $0.326B 0.00
Cerus (CERS) United States $0.310B 0.00
OraSure Technologies (OSUR) United States $0.287B 19.25
Zynex (ZYXI) United States $0.258B 54.07
Aurora Cannabis (ACB) Canada $0.236B 0.00
TerrAscend (TSNDF) Canada $0.224B 0.00
Utah Medical Products (UTMD) United States $0.219B 15.12
High Tide (HITI) Canada $0.215B 89.00
MacroGenics (MGNX) United States $0.201B 0.00
Sanuwave Health (SNWV) United States $0.189B 2.67
Jin Medical (ZJYL) China $0.166B 0.00
Organigram Holdings (OGI) Canada $0.164B 0.00
Brainsway (BWAY) Israel $0.164B 98.40
Zevia PBC (ZVIA) United States $0.150B 0.00
FitLife Brands (FTLF) United States $0.147B 18.50
TriSalus Life Sciences (TLSI) United States $0.135B 0.00
Fonar (FONR) United States $0.104B 11.75
Quipt Home Medical (QIPT) United States $0.102B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.093B 23.10
Veru (VERU) United States $0.092B 0.00
Ayr Wellness (AYRWF) United States $0.079B 0.00
Rockwell Medical (RMTI) United States $0.071B 36.67
Exagen (XGN) United States $0.069B 0.00
Modular Medical (MODD) United States $0.067B 0.00
Cellectar Biosciences (CLRB) United States $0.065B 0.00
Jushi Holdings (JUSHF) United States $0.063B 0.00
InterCure (INCR) Israel $0.061B 0.00
MariMed (MRMD) United States $0.059B 0.00
Safety Shot (SHOT) United States $0.053B 0.00
Apyx Medical (APYX) United States $0.053B 0.00
Cytosorbents (CTSO) United States $0.049B 0.00
Allurion Technologies (ALUR) United States $0.033B 0.00
ImmuCell (ICCC) United States $0.033B 0.00
Flora Growth (FLGC) United States $0.018B 0.00
Meihua Medical Technologies (MHUA) China $0.017B 0.00
Innovative Eyewear (LUCY) United States $0.016B 0.00
Nephros (NEPH) United States $0.016B 0.00
Trinity Biotech (TRIB) Ireland $0.010B 0.00
NeuroMetrix (NURO) United States $0.008B 0.00
Sharps Technology (STSS) United States $0.006B 0.00
IM Cannabis (IMCC) Canada $0.006B 0.00
Agape ATP (ATPC) $0.006B 0.00
Leafly Holdings (LFLY) United States $0.005B 0.00
Senestech (SNES) United States $0.002B 0.00
Akanda (AKAN) United Kingdom $0.002B 0.00
GlucoTrack (GCTK) United States $0.001B 0.00
InVivo Therapeutics Holdings (NVIVQ) United States $0.001B 0.00
United-Guardian (UG) United States $0.000B 12.83
SNDL (SNDL) Canada $0.000B 0.00